Go Pro

5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Ryan Hasson
About The Author

Ryan Hasson

Contributing Author

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
AbbVie (ABBV)
4.6539 of 5 stars
$264.61-0.1%2.62%74.75Moderate Buy$275.95
Mondelez International (MDLZ)
4.4823 of 5 stars
$64.700.4%3.09%23.79Moderate Buy$67.30
ExxonMobil (XOM)
3.8673 of 5 stars
$163.90-0.7%2.51%21.09Hold$166.10
Schwab US Dividend Equity ETF (SCHD)N/A$35.210.3%2.95%14.57Moderate Buy$35.21
NEOS Nasdaq 100 High Income ETF (QQQI)N/A$53.84-0.7%14.19%32.88Moderate Buy$53.84
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines